Imeglyn 500 Tablet contains Imeglimin 500 mg, an oral antihyperglycemic agent indicated for the treatment of type 2 diabetes mellitus. Imeglimin is a novel tetrahydrotriazine compound that improves glycemic control by targeting mitochondrial bioenergetics, thereby enhancing insulin sensitivity and promoting glucose-dependent insulin secretion. It acts through a dual mechanism involving the restoration of mitochondrial function and reduction of oxidative stress, leading to improved pancreatic β-cell function and decreased hepatic glucose production. Imeglyn 500 is typically prescribed as monotherapy or in combination with other antidiabetic agents, including metformin, sulfonylureas, or DPP-4 inhibitors, to achieve optimal glycemic control. Clinical studies have demonstrated its efficacy in lowering HbA1c levels and fasting plasma glucose with a favorable safety profile. Common adverse effects are generally mild and may include gastrointestinal disturbances such as nausea and diarrhea. Imeglyn 500 should be used with caution in patients with renal or hepatic impairment, and dosage adjustments may be necessary. Regular monitoring of blood glucose levels and renal function is recommended during therapy. This medication should be prescribed and used under the supervision of a healthcare professional experienced in diabetes management.